AZD1208

• Description:

  AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; Pim

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; JAK/STAT Signaling

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AZD1208.html

• Purity:

  99.73

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C (NC/1=O) SC1=C/C2=C (N3C[C@H] (N) CCC3) C (C4=CC=CC=C4) =CC=C2

• Molecular Formula:

  C21H21N3O2S

• Molecular Weight:

  379.48

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22 (14) :4599-604.|[2]Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205.|[3]Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6 (35) :37930-47.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  PIM2

• CAS Number:

  1204144-28-4